Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
Holdings in Q2 2026
Holdings as of Jun 30, 2026, filed Aug 13, 2026. Long positions only; changes compare share counts with Q1 2026.
- Positions
- 104
- +9 vs. Q1 2026
- Portfolio value
- $2.04B
- +$339.7M (+19.9%) vs. Q1 2026
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals, Inc.77313F114 | *W EXP 09/02/202 | 75,000 | $278 | <0.1% | 00.0% | Unchanged | – |
| ADGMAdagio Medical Holdings, Inc. | COM | 80,000 | $52.1K | <0.1% | 00.0% | Unchanged | History |
| NXTCNextCure, Inc. | COM NEW | 41,960 | $67.1K | <0.1% | −199,866−82.6% | Reduced | History |
| OBIOOrchestra BioMed Holdings, Inc. | COM | 33,400 | $144.1K | <0.1% | −369,150−91.7% | Reduced | History |
| QTTBQ32 Bio Inc. | COM | 27,777 | $353.9K | <0.1% | 00.0% | Unchanged | History |
| LENZLENZ Therapeutics, Inc. | COM | 100,000 | $568.0K | <0.1% | 00.0% | Unchanged | History |
| BOLDBoundless Bio, Inc. | COM | 250,000 | $625.0K | <0.1% | +250,000 | New | History |
| XFORX4 Pharmaceuticals, Inc | COM NEW | 145,000 | $677.1K | <0.1% | 00.0% | Unchanged | History |
| ENGNenGene Therapeutics Inc. | COM | 600,000 | $1.04M | 0.1% | −10,370−1.7% | Reduced | History |
| OKUROnKure Therapeutics, Inc. | COM CL A | 240,963 | $1.10M | 0.1% | 00.0% | Unchanged | History |
| EIKNEikon Therapeutics, Inc. | COM | 98,001 | $1.28M | 0.1% | +98,001 | New | History |
| SPRBSpruce Biosciences, Inc. | COM NEW | 30,000 | $1.62M | 0.1% | +30,000 | New | History |
| ANLAdlai Nortye Group Ltd. | ADS | 153,847 | $1.77M | 0.1% | −10,901−6.6% | Reduced | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 98,999 | $1.78M | 0.1% | +98,999 | New | History |
| NMRANeumora Therapeutics, Inc. | COM | 1,070,651 | $1.82M | 0.1% | +1,070,651 | New | History |
| JATTJATT II Acquisition Corp. | ORD SHS | 200,000 | $2.27M | 0.1% | +200,000 | New | History |
| Celcuity Inc.15102KAB6 | NOTE 0.250% 8/0 | – | $2.28M | 0.1% | – | New | – |
| OACCUOaktree Acquisition Corp. III Life Sciences | UNIT 10/04/2029 | 250,000 | $2.75M | 0.1% | 00.0% | Unchanged | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 75,000 | $2.81M | 0.1% | 00.0% | Unchanged | History |
| SGPSpyGlass Pharma, Inc. | COM SHS | 131,586 | $2.93M | 0.1% | −118,414−47.4% | Reduced | History |
| ALECAlector, Inc. | COM | 1,510,000 | $3.04M | 0.1% | +1,010,000+202.0% | Added | History |
| KPTIKaryopharm Therapeutics Inc. | COM NEW | 312,500 | $3.05M | 0.1% | −187,500−37.5% | Reduced | History |
| FTHFaeth Therapeutics, Inc. | COM NEW | 144,404 | $3.61M | 0.2% | +144,404 | New | History |
| BHVNBiohaven Ltd. | COM | 250,000 | $3.72M | 0.2% | +250,000 | New | History |
| AMANAmanat Acquisition Corp. | CL A ORD | 375,000 | $3.81M | 0.2% | +375,000 | New | History |
| IMVTImmunovant, Inc. | COM | 100,000 | $3.85M | 0.2% | 00.0% | Unchanged | History |
| RACCResearch Alliance Corp III | ORD SHS CL A | 370,000 | $3.96M | 0.2% | +370,000 | New | History |
| MBXMBX Biosciences, Inc. | COM | 75,000 | $4.14M | 0.2% | −75,000−50.0% | Reduced | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 301,183 | $4.26M | 0.2% | −807,300−72.8% | Reduced | History |
| VRCAVerrica Pharmaceuticals Inc. | COM SHS | 707,338 | $4.33M | 0.2% | 00.0% | Unchanged | History |
| AVBPArriVent BioPharma, Inc. | COM | 125,000 | $4.34M | 0.2% | −50,000−28.6% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 250,000 | $4.59M | 0.2% | 00.0% | Unchanged | History |
| COAGHemab Therapeutics Holdings, Inc. | COM SHS | 138,030 | $5.07M | 0.2% | +138,030 | New | History |
| DTILPrecision Biosciences Inc | COM NEW | 646,576 | $5.08M | 0.2% | +48,630+8.1% | Added | History |
| RZLTRezolute, Inc. | COM NEW | 1,000,000 | $5.20M | 0.3% | −547,641−35.4% | Reduced | History |
| ASMBAssembly Biosciences, Inc. | COM NEW | 190,000 | $5.22M | 0.3% | +190,000 | New | History |
| NAMSWNewAmsterdam Pharma Co N.V. | *W EXP 11/22/202 | 245,000 | $5.34M | 0.3% | 00.0% | Unchanged | History |
| CRSPCRISPR Therapeutics AG | NAMEN AKT | 100,000 | $5.45M | 0.3% | −50,000−33.3% | Reduced | History |
| MGNXMacrogenics Inc | COM | 1,216,606 | $5.62M | 0.3% | +716,606+143.3% | Added | History |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 1,525,000 | $5.95M | 0.3% | +950,000+165.2% | Added | History |
| SLGLSol-Gel Technologies Ltd. | SHS NEW | 84,900 | $6.29M | 0.3% | +49,900+142.6% | Added | History |
| TYRATyra Biosciences, Inc. | COM | 200,012 | $6.39M | 0.3% | −57,500−22.3% | Reduced | History |
| GENBGenerate Biomedicines, Inc. | COM SHS | 400,000 | $6.75M | 0.3% | +50,000+14.3% | Added | History |
| IBIOiBio, Inc. | COM NEW | 4,007,881 | $7.01M | 0.3% | +900,681+29.0% | Added | History |
| ASNDAscendis Pharma A/S | ORD SHS | 30,000 | $8.00M | 0.4% | −65,000−68.4% | Reduced | History |
| QUREuniQure N.V. | SHS | 175,000 | $8.06M | 0.4% | +175,000 | New | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 1,464,303 | $8.64M | 0.4% | −1,100,000−42.9% | Reduced | History |
| AVRAnteris Technologies Global Corp. | COM | 912,397 | $8.99M | 0.4% | 00.0% | Unchanged | History |
| KRROKorro Bio, Inc. | COM | 706,904 | $9.32M | 0.5% | 00.0% | Unchanged | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 275,000 | $9.32M | 0.5% | 00.0% | Unchanged | History |
| PRQRProQR Therapeutics N.V. | SHS EURO | 5,543,936 | $10.3M | 0.5% | +3,089,658+125.9% | Added | History |
| VERAVera Therapeutics, Inc. | CL A | 250,000 | $10.7M | 0.5% | 00.0% | Unchanged | History |
| EPRXEupraxia Pharmaceuticals Inc. | COM | 1,650,000 | $10.9M | 0.5% | +60,995+3.8% | Added | History |
| DMRADamora Therapeutics, Inc. | COM NEW | 425,000 | $11.1M | 0.5% | −25,000−5.6% | Reduced | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 1,750,000 | $11.9M | 0.6% | +750,000+75.0% | Added | History |
| Omeros Corp682143AK8 | NOTE 9.500% 6/1 | – | $12.2M | 0.6% | – | – | – |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 150,000 | $12.2M | 0.6% | −50,000−25.0% | Reduced | History |
| MANEVeradermics, Inc | COMMON STOCK | 100,000 | $12.3M | 0.6% | +30,000+42.9% | Added | History |
| TEVATeva Pharmaceutical Industries Ltd | SPONSORED ADS | 374,000 | $12.7M | 0.6% | −1,026,000−73.3% | Reduced | History |
| CLYMClimb Bio, Inc. | COM | 972,000 | $12.7M | 0.6% | +272,000+38.9% | Added | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 148,013 | $12.7M | 0.6% | +48,013+48.0% | Added | History |
| EQEquillium, Inc. | COM | 4,100,000 | $13.1M | 0.6% | +2,873,690+234.3% | Added | History |
| HLXCHelix Acquisition Corp. III | USD CL A ORD SHS | 1,250,000 | $13.3M | 0.7% | 00.0% | Unchanged | History |
| Cogent Biosciences, Inc.19240QAA0 | NOTE 1.625%11/1 | – | $13.7M | 0.7% | – | – | – |
| ODTXOdyssey Therapeutics, Inc. | COMMON STOCK | 766,346 | $14.3M | 0.7% | +766,346 | New | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 4,214,582 | $14.4M | 0.7% | +1,050,000+33.2% | Added | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 400,000 | $14.9M | 0.7% | +400,000 | New | History |
| SVRASavara Inc | COM | 2,512,153 | $15.5M | 0.8% | 00.0% | Unchanged | History |
| CGEMCullinan Therapeutics, Inc. | COM | 875,760 | $15.9M | 0.8% | +94,500+12.1% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 300,000 | $17.0M | 0.8% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 450,000 | $17.4M | 0.9% | −300,000−40.0% | Reduced | History |
| JBIOJade Biosciences, Inc. | COM NEW | 840,350 | $18.7M | 0.9% | +200,394+31.3% | Added | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 2,497,864 | $19.3M | 0.9% | +1,629,844+187.8% | Added | History |
| RLAYRelay Therapeutics, Inc. | COM | 1,050,000 | $19.6M | 1.0% | +650,000+162.5% | Added | History |
| MLYSMineralys Therapeutics, Inc. | COM | 750,000 | $20.2M | 1.0% | 00.0% | Unchanged | History |
| PTGXProtagonist Therapeutics, Inc | COM | 172,125 | $21.1M | 1.0% | 00.0% | Unchanged | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 40,000 | $21.5M | 1.1% | −15,000−27.3% | Reduced | History |
| ANROAlto Neuroscience, Inc. | COM SHS | 850,000 | $22.4M | 1.1% | +350,000+70.0% | Added | History |
| NRIXNurix Therapeutics, Inc. | COM | 967,620 | $23.5M | 1.1% | 00.0% | Unchanged | History |
| FBRXForte Biosciences, Inc. | COM NEW | 1,145,391 | $24.3M | 1.2% | +133,501+13.2% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 500,000 | $25.4M | 1.2% | −86,904−14.8% | Reduced | History |
| BLTEBelite Bio, Inc | SPONSORED ADS | 165,000 | $25.4M | 1.2% | +100,000+153.8% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 700,000 | $26.0M | 1.3% | +200,000+40.0% | Added | History |
| LXEOLexeo Therapeutics, Inc. | COM | 5,807,611 | $27.0M | 1.3% | +757,400+15.0% | Added | History |
| OVIDOvid Therapeutics Inc. | COM | 10,144,562 | $27.3M | 1.3% | −491,756−4.6% | Reduced | History |
| TRVITrevi Therapeutics, Inc. | COM | 1,800,172 | $33.6M | 1.6% | −200,000−10.0% | Reduced | History |
| NUVLNuvalent, Inc. | COM | 275,000 | $34.0M | 1.7% | −25,000−8.3% | Reduced | History |
| STROSutro Biopharma, Inc. | COM SHS | 1,172,487 | $38.9M | 1.9% | +102,968+9.6% | Added | History |
| DNTHDianthus Therapeutics, Inc. | COM | 400,000 | $39.0M | 1.9% | +50,000+14.3% | Added | History |
| TRAXFirst Tracks Biotherapeutics, Inc. | ORD SHS | 2,032,012 | $40.9M | 2.0% | +2,032,012 | New | History |
| ABVXAbivax S.A. | SPONSORED ADS | 330,000 | $44.0M | 2.2% | −75,000−18.5% | Reduced | History |
| RVMDRevolution Medicines, Inc. | COM | 250,000 | $46.8M | 2.3% | +150,000+150.0% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 550,000 | $46.9M | 2.3% | −150,483−21.5% | Reduced | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 2,900,000 | $53.6M | 2.6% | +1,559,160+116.3% | Added | History |
| ANABAnaptysbio, Inc | COM | 826,109 | $55.8M | 2.7% | −113,891−12.1% | Reduced | History |
| ORKAOruka Therapeutics, Inc. | COM | 590,000 | $56.2M | 2.7% | +90,327+18.1% | Added | History |
| ALKSAlkermes plc. | SHS | 1,125,000 | $58.9M | 2.9% | −225,000−16.7% | Reduced | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 185,000 | $61.9M | 3.0% | +15,000+8.8% | Added | History |
| INSMINSMED Inc | COM PAR $.01 | 650,000 | $69.3M | 3.4% | +170,000+35.4% | Added | History |
| ERASErasca, Inc. | COM | 5,250,000 | $96.2M | 4.7% | −100,000−1.9% | Reduced | History |
Options (8)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| MRNAModerna, Inc. | Stock | $35.0M | $33.3M |
| ARK ETF Tr00214Q302 | GENOMIC REV ETF | – | $31.5M |
| LLYEli Lilly & Co | Stock | – | $24.0M |
| OMEROmeros Corp | COM | $13.4M | – |
| ALKSAlkermes plc. | SHS | – | $13.1M |
| QUREuniQure N.V. | SHS | – | $9.21M |
| EVMNEvommune, Inc. | COM SHS | $6.65M | – |
| SMMTSummit Therapeutics Inc. | COM | – | $1.46M |
Sold out since Q1 2026 (8)
Positions held at the end of Q1 2026 that are gone from this filing.
| Security | Class | Shares in Q1 2026 | Value in Q1 2026 | % of portfolio in Q1 2026 | History |
|---|---|---|---|---|---|
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 1,400,000 | $55.6M | 3.3% | History |
| ACLXArcellx, Inc. | COMMON STOCK | 362,764 | $41.7M | 2.4% | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 562,631 | $29.7M | 1.7% | History |
| BBIOBridgeBio Pharma, Inc. | COM | 150,000 | $11.1M | 0.7% | History |
| WVEWave Life Sciences, Inc. | SHS | 1,401,727 | $10.2M | 0.6% | History |
| Celcuity Inc.15102KAA8 | NOTE 2.750% 8/0 | – | $7.31M | 0.4% | – |
| CORTCorcept Therapeutics Inc | COM | 50,000 | $2.02M | 0.1% | History |
| KZRKezar Life Sciences, Inc. | COM | 229,076 | $1.70M | 0.1% | History |